Takeda Presents New Data at the Endocrine Society』s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (「Takeda」) this week shared new data revealing the burden of chronic hypoparathyroidism on patients and …